Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 124,998 shares of Adaptive Biotechnologies stock in a transaction on Monday, January 5th. The shares were sold at an average price of $15.59, for a total transaction of $1,948,718.82. Following the completion of the sale, the chief executive officer directly owned 2,584,243 shares in the company, valued at $40,288,348.37. This represents a 4.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Adaptive Biotechnologies Stock Up 3.8%

Shares of NASDAQ ADPT traded up $0.62 during trading on Wednesday, hitting $16.73. The company had a trading volume of 2,068,620 shares, compared to its average volume of 2,099,863. The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of -30.98 and a beta of 2.18. The stock has a fifty day simple moving average of $16.50 and a two-hundred day simple moving average of $14.24. Adaptive Biotechnologies Corporation has a fifty-two week low of $5.97 and a fifty-two week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The firm had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. During the same quarter in the prior year, the firm earned ($0.22) EPS. The company’s revenue for the quarter was up 102.4% on a year-over-year basis. On average, analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. JPMorgan Chase & Co. boosted their price target on Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Morgan Stanley assumed coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price for the company. Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday. Piper Sandler increased their price objective on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, October 15th. Finally, Wall Street Zen upgraded Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $17.11.

Hedge Funds Weigh In On Adaptive Biotechnologies

Several large investors have recently modified their holdings of the business. Sound Income Strategies LLC acquired a new stake in shares of Adaptive Biotechnologies during the 3rd quarter worth about $30,000. Smartleaf Asset Management LLC boosted its stake in Adaptive Biotechnologies by 593.5% during the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock worth $59,000 after buying an additional 3,371 shares during the period. Caxton Associates LLP acquired a new stake in shares of Adaptive Biotechnologies during the first quarter valued at about $93,000. Teza Capital Management LLC purchased a new stake in shares of Adaptive Biotechnologies in the 1st quarter valued at approximately $118,000. Finally, Quadrant Capital Group LLC acquired a new position in shares of Adaptive Biotechnologies in the 3rd quarter worth approximately $133,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.